Autologous skin equivalent grafts (Institut National de la Santé Et de la Recherche Médicale)

N/A

Report date: 2023/10/26 16:51:05

Base Information

Drug NameAutologous skin equivalent grafts (Institut National de la Santé Et de la Recherche Médicale)

Drug Alias NameCOL7A1-SIN retroviral vector engineered autologous tissue-engineered skinAutologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral Vector

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Skin cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionTissue replacementsCOL7 gene transference

TargetsCollagen alpha-1(VII) chain

Therapy Area/IndicationsEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitut National De La Santé Et De La Recherche Médicale

China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale Rouen U1096 Institut National De La Santé Et De La Recherche Médicale, France U979

Inactive CompaniesN/A

Active IndicationsEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa

Inactive IndicationsN/A

Other Information

ATC CodeN/A